Tissue Regenix Group Plc (TRX)

London
0.652
+0.002(+0.31%)
  • Volume:
    2,957,846
  • Bid/Ask:
    0.640/0.670
  • Day's Range:
    0.648 - 0.669

TRX Overview

Prev. Close
0.65
Day's Range
0.648-0.669
Revenue
12.82M
Open
0.654
52 wk Range
0.3-0.93
EPS
0
Volume
2,957,846
Market Cap
45.86M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
21,031,961
P/E Ratio
-
Beta
2.41
1-Year Change
4,676.12%
Shares Outstanding
7,033,077,499
Next Earnings Date
30 Aug 2021
What is your sentiment on Tissue Regenix Group Plc?
or
Market is currently closed. Voting is open during market hours.

Tissue Regenix Group Plc News

Tissue Regenix Group Plc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellNeutralSell
Technical IndicatorsSellSellStrong BuySellStrong Buy
SummarySellSellNeutralNeutralNeutral

Tissue Regenix Group Plc Company Profile

Tissue Regenix Group Plc Company Profile

Employees
78

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, Cardiac, and GBM-V divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material to reduce risk of injection; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for orthopaedics, trauma, and woundcare; DermaPure Non-Oriented Decellularised allograft dermal tissue for urogynaecology and general surgery; and SurgiPure XD, Decellularised xenograft dermal tissue for the repair of hernias and/or body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient’s own cells; ConCelltrate 100, a verified osteoinductive bone matrix for orthopaedics and spine; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedics, trauma, and spine; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure product; Matrix OI 100 DBM for spine and non-structural bone-grafting; Matrix OI Strips and Blocks, a cell containment scaffold; AmnioWorks for ophthalmology; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

Read More
  • Below is a comprehensive background research article on TRX
    0
    • https://www.reddit.com/user/Jessie1991a/comments/krab7q/jessies_first_write_up/
      0
      • This stock has a huge potential medium/long term
        0
        • https://metro.co.uk/2021/02/18/scientists-regrow-and-repair-liver-from-lab-grown-cells-in-world-first-14098497/
          0
          • will this keep going up? thoughts?
            0
            • Regenerative medicine is the future
              0
              • what are people thinking
                3
                • Moving well today. Let's hope we see 8p again in 2020.
                  1
                  • The rise will happen just need to be patience and hold stock.
                    1
                    • Holding
                      0
                  • Will it go that far today
                    0
                    • Still not too late to catch the rise to 5p
                      3
                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.